Edgar Filing: Stelzer Laurie - Form 4

Stelzer Laur	rie									
Form 4	2010									
February 14	ЛЛ								PPROVAL	
Check th if no lon subject to Section Form 4 of Form 5 obligation may com <i>See</i> Instr 1(b).	nis box Iger o 16. or Filed pur Das Section 17(UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							3235-0287 January 31, 2005 average Jirs per . 0.5	
(Print or Type	Responses)									
Stelzer Laurie Sym HA			Symbol HALO	2. Issuer Name and Ticker or Trading ymbol IALOZYME THERAPEUTICS NC [HALO]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
	· · · ·	388		of Earliest Tr Day/Year) 2019	ransaction		Director X Officer (giv below) SVP, Ch		% Owner her (specify fficer	
				If Amendment, Date Original iled(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
(City)	(State)	(Zip)	T 1		.	a	Person	6 D C .		
1.Title of Security (Instr. 3)	2. Transaction Date	ion Date 2A. Deemed y/Year) Execution Date, if any (Month/Day/Year)		Code Disposed of (D)		5. Amount of Securities Beneficially Owned		7. Nature of Indirect		
Reminder: Re	port on a separate line	e for each cla	uss of sec	urities benef	ficially ow	ned directly of	or indirectly.			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Stelzer Laurie - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Securitie (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amou or Numb of Sha
Option to Purchase Common Stock	\$ 16.65	02/12/2019		A	85,922	02/12/2020(1)	02/12/2029	Common Stock	85,9
Restricted Stock Units	\$ 0	02/12/2019		А	45,046	02/12/2020(2)	(2)	Common Stock	45,0

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Stelzer Laurie C/O HALOZYME THERAPEUTICS, INC. 11388 SORRENTO VALLEY ROAD SAN DIEGO, CA 92121			SVP, Chief Financial Officer				
Signatures							
/s/ James R. Oehler as attorney-in-fact for La Stelzer	urie	02/1	4/2019				
** Signature of Reporting Person		Ι	Date				
Explanation of Response	s:						

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This option vests one-fourth on such date and then 1/48th monthly thereafter.

(2) This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.